AtaiBeckley (ATAI) Proxy filing summary

Executive summary

• AtaiBeckley has entered into a definitive agreement to be acquired by Eli Lilly and Company, aiming to accelerate the development and global reach of its mental health therapies.

• All ongoing clinical studies will continue as planned, with no expected disruptions to site operations, patient care, or study timelines.

• The transaction is positioned to leverage Lilly's global infrastructure to advance AtaiBeckley's programs to approval and patient access.

Voting matters and shareholder proposals

• Stockholders will be asked to approve the agreement and plan of merger at a special meeting, with proxy materials to be distributed following SEC filing.

• Shareholders are encouraged to review the proxy statement and related materials for important information regarding the merger.

Board of directors and corporate governance

• Certain directors, executive officers, and employees may be deemed participants in the proxy solicitation for the merger.

• Information on director and executive officer ownership and compensation is available in the 2026 Proxy Statement and recent SEC filings.